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Abstract
Background: Rheumatic Heart Disease (RHD) is a disease of poverty that is neglected in developing countries,
including South Africa. Lack of adequate evidence regarding the cost of RHD care has hindered national and
international actions to prevent RHD related deaths. The objective of this study was to estimate the cost of RHD-
related health services in a tertiary hospital in the Western Cape, South Africa.
Methods: The primary data on service utilisation were collected from a randomly selected sample of 100 patient
medical records from the Global Rheumatic Heart Disease Registry (the REMEDY study) - a registry of individuals
living with RHD. Patient-level clinical data, including, prices and quantities of medications and laboratory tests, were
collected from the main tertiary hospital providing RHD care. All annual costs from a health system perspective
were estimated in 2017 (base year) in South African Rand (ZAR) using a combination of ingredients and step-down
costing approaches and later converted to United States dollars (USD). Step-down costing was used to estimate
provider time costs and all other facility costs such as overheads. A 3% discount rate was also employed in order to
allow depreciation and opportunity cost. We aggregated data to estimate the total annual costs and the average
annual per-patient cost of RHD and conducted a one-way sensitivity analysis.
Results: The estimated total cost of RHD care at the tertiary hospital was USD 2 million (in 2017 USD) for the year
2017, with surgery costs accounting for 65%. Per-patient, average annual costs were USD 3900. For the subset of
costs estimated using the ingredients approach, outpatient medications, and consumables related to cardiac
catheterisation and heart valve surgery were the main cost drivers.
Conclusions: RHD-related healthcare consumes significant tertiary hospital resources in South Africa, with annual
per-patient costs higher than many other non-communicable and infectious diseases. This analysis supports the
scaling up of primary and secondary prevention programmes at primary health centers in order to reduce future
tertiary care costs. The study could also inform resource allocation efforts and provide cost estimates for future
studies of intervention cost-effectiveness.
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Background
In South Africa, private and public health systems exist
in parallel. The public health system services over 80%
of the population [1]. Currently, the public health system
is largely funded through allocations from general tax
revenue and small contributions acquired from the local
government revenue and user charges [1, 2]. However,
the country’s public health sector continues to face
many challenges - ranging from a shortage of resources
to a growing and ageing population and the high burden
of diseases [1–3]. Mainly, non-communicable diseases
(NCDs) have become a public health issue requiring ur-
gent attention. One preventable and treatable but
neglected form of NCD is rheumatic heart disease
(RHD) [4].
Rheumatic heart disease (RHD) is the most common
acquired cardiovascular disease among children and ado-
lescents in low- and middle-income countries [5]. It is a
chronic inflammatory disease of the heart valves that re-
sults from recurrent episodes of acute rheumatic fever
(ARF). RHD often leads to heart failure, stroke, and pre-
mature death, including among children and young
adults [5, 6]. A recent study estimated about 33 million
prevalent cases and 320,000 deaths from RHD globally
in 2015 [6]. African countries have some of the highest
rates of RHD in the world [6, 7].
Previous studies from higher-income regions suggest
that RHD is a high-cost disease because of its clinical
complexity fuelled by frequent and lengthy hospital ad-
missions and expensive surgical care; as well as the sig-
nificant physical and psychological impact on patients
and households [8]. The condition results in high levels
of resource use, particularly in middle-income countries
where access to advanced cardiovascular services, in-
cluding heart valve surgery, is increasing [8, 9]. Even
though surgery can save or prolong life, access remains
low in many countries due to shortages in surgical ser-
vices themselves as well as a lack of early diagnosis and
prompt referral [10]. It is also unclear whether cardiac
surgery programmes are fiscally sustainable in low- and
middle-income countries [5, 11].
Lack of information on the cost of RHD is a barrier to
assessing and distributing an equitable allocation of re-
sources between RHD and other diseases and to analys-
ing the cost-effectiveness of new RHD intervention or
prevention strategies compared to existing strategies
[12]. A recent review found very few studies on the eco-
nomics of RHD and no studies of the cost of care in the
African context [9–12]. The objective of the present
study was to estimate the cost of care for RHD from the
public health system (provider) perspective at a tertiary
hospital in South Africa. We look at outpatient costs
and inpatient costs at four different levels of care – out-
patient care, cardiac intensive unit (ICU) care, cardiac
catheterisation laboratory, and cardiac surgical theatre
care – that are the major clinical areas/levels where indi-
viduals with RHD receive cardiac services (and incur
costs) in the South African context.
Methods
Study setting and population
This cross-sectional cost analysis study was carried out
in 2017 at Groote Schuur Hospital (GSH), a public ter-
tiary level healthcare facility that serves the Western
Cape Province. We focused on estimating (a) the total
costs incurred at GSH in 2017 because of RHD and (b)
the per-patient annual cost of care using a representative
sample of individuals requiring tertiary care at GSH. The
RHD Pathway of Care (presented in Additional file 1:
Appendix 1) is often different, and most cases are refer-
rals from outside GSH.
Identifying clients with RHD
In this study, cost data from GSH were complemen-
ted with more detailed data on patient utilisation of
health services. These were obtained from randomly
selected participants (n = 100) in the Global Rheum-
atic Heart Disease Registry (the REMEDY study), an
international registry of RHD that includes cases en-
rolled at GSH [13].
The REMEDY study recruited 448 participants from
GSH over 2012–2014. Research staff reviewed and se-
lected new patient folders, separately documenting
current patterns of disease pathology and care delivery
in order to investigate the clinical epidemiology of RHD.
The observational REMEDY study did not provide any
care to RHD patients; however, they captured major ad-
verse events and instances of defaulting on medications
or other aspects of care over a 24-month follow-up. We
randomly sampled 100 of the 448 REMEDY participants
in order to calculate parameters related to healthcare
utilisation.
It is important to note that subjects who enrolled
in REMEDY rarely utilised emergency departments
(ED) because they were generally clinically stable, vis-
iting GSH outpatient departments twice yearly on
average to evaluate progression. In addition, pharmacy
(refill) visits are few and are much less resource-
demanding compared to clinical follow-ups; often, pa-
tients collect pre-packed and dispensed medications
from a third-party provider. This situation made it
challenging to defining the input and outcome guides
for ED and pharmacy encounters at the individual,
population and system levels. Consequently, we did
not attempt to estimate pharmacy visit or emergency
department costs outside GSH.
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Costing approach
We calculated the economic cost of providing RHD care
from the health system (provider) perspective. Retro-
spective costing was conducted using a mix of the ingre-
dients and step-down approach by aggregating costs at
different levels. All data were collected from January
2017 to December 2017. Costs were calculated in ZAR
using 2017 as the base year and later converted to USD.
We used a set of four data collection instruments, one
for each of the major clinical units where RHD care is
delivered at GSH: cardiac clinic, medical and ICU ward,
cardiac catheterisation laboratory, and surgical theatre.
Ingredients costing
This approach primarily used detailed medical records
and observations to measure the specific resources re-
quired for delivering RHD care. We studied utilisation
patterns of resources such as medications, laboratory
tests, and diagnostics and consumables related to RHD
care. For example, the cost of medication was estimated
according to the number of medications recorded as dis-
pensed for each of the 100 REMEDY participants then
multiplied by the cost per dosage/injection. We also
reviewed REMEDY and other hospital medical records
to establish utilisation rates for specific services, and
semi-structured interviews with clinical experts in RHD
care were also conducted. The cost-share of cardiac
medical and ICU care on RHD was calculated using the
number of inpatient bed-days at GSH; i.e. by multiplying
the number of admissions with the average length of
stay. The average length of stay of individuals with RHD
in the cardiac wards was 4.7 days per admission accord-
ing to the most recent annual report.
We obtained pricelists for commodities from the
Western Cape Department of Health (Wendy Braynt,
2018 - personal communication, 8 November). As per
treatment guidelines and the data obtained from medical
records, direct medical costs were calculated using the
accounting identity; i.e. costs incurred are the product of
prices and quantities of goods and services consumed.
Step-down costing
Step-down costing approach is commonly used to esti-
mate costs that are long-term but not directly related to
the patient utilisation, including costs borne by support
departments in health facilities [14]. Capital costs (e.g.
medical building, equipment and furniture) and recur-
rent indirect costs (e.g. overhead costs incurred by GSH,
electricity, water, cleaning, security) of proving RHD
care were costed using the step-down approach.
Capital item costs and useful lifetimes were obtained
from the hospital procurement department. Original
costs obtained were also inflated to 2017 levels using the
consumer price index [14]. Equipment and furniture
item costs were apportioned to RHD care according to
the share of RHD patients using the items. Building
costs were estimated using a square meter of space ap-
portioned for RHD care. Costs were calculated by multi-
plying by the building replacement value per square
meter (USD 3200), which was obtained from the build-
ing and engineering company-approved tender estimate
for GSH [15]. Recurrent cost data were obtained from
the finance department of GSH for the 2016/2017 finan-
cial year.
As recommended by the World Health Organization
(WHO), capital items were discounted and annualised
using a discount factor of 3%, reflecting depreciation
and the opportunity cost of purchasing the capital
items [16]. An estimated lifetime of 30 years for
buildings and ten years for equipment and furniture
were used. Sensitivity analyses were conducted using
0, 5 and 10% (which is a government bond rate in
South Africa) discount rates to verify the robustness
of the results [16, 17].
Costs were categorised into overheads (i.e. not directly
associated with caring) and final service centers (i.e. used
in care) [18]. Overhead costs comprise the cost of gen-
eral support services departments that are important for
the facility to operate [14, 16]. These include utilities
(i.e. electricity, water), non-clinical personnel (i.e. clean-
ing, security) as well as stores that provide non-patient
specific services [16, 17]. Overhead costs were estimated
by assessing the overhead expenditures, assuming that
all patients utilised equal amounts of overhead costs per
unit time when they visit GSH [17, 18].
The calculation for overhead costs per visit was the
annual overhead expenditure divided by the annual
number of patient visits. This approach was used for
both outpatient and inpatient departments of GSH be-
cause the cost centre accounting system does not exist
in the hospital. Overhead expenditures were allocated
directly to outpatients and inpatient departments using
an allocation factor based on the patient day equivalent
(PDE) concept [17]. PDE is estimated as:
PDEoutpatients ¼ annual inpatient daysð Þ  1
weighting factor
Þ
þ annual outpatient visitsð Þ
PDEinpatients ¼ annual inpatient daysð Þ
þ annual outpatient visits  weighting factorð Þ
The local practice at the University of Cape Town is
to employ the (empirically-based) rule of thumb that an
outpatient visits costs one-third (1/3 = 0,33) of an in-
patient day, and this is used as a weighing factor [17].
Overhead costs per outpatient visit and inpatient day at
GSH are therefore expressed as:
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Overhead cost per outpatient visit ¼ annual overhead expenditure
PDEoutpatients:
Overhead cost per inpatient day ¼ annual overhead expenditure
PDEinpatients
Costs of different centers within GSH that render ser-
vices to the entire hospital (i.e. intermediate costs) were
incorporated in overhead costing; these included the
pharmacy and laboratory departments [18]. These inter-
mediate and overhead costs were later added to the final
cost department in a sequential manner. Recurrent and
capital costs were also allocated to the four clinical units
directly according to their actual resource utilisation.
For instance, estimates of square meters of space used
directly for care were used to distribute the building
costs to the four units where RHD care is provided. In-
curred recurrent and capital costs were distributed ac-
cording to the clinical unit using allocation bases and
resource usage. The number of individuals with RHD as
a percentage of the total number of patients served in
each clinical unit was used to calculate a utilisation fac-
tor reflecting the share of costs allocable to RHD.
There was no financial cost incurred by GSH for train-
ing nurses or other staff personnel specific to RHD;
however, lectures were given by senior registrars to
nursing staff every Tuesday; nurses also had an oppor-
tunity to participate in catheterisation procedures to
teach them about post-procedure care. We excluded the
economic cost component of these lectures.
Personnel costing
Statistics regarding time allocation and time spent by
different personnel providing care or consulting patients
with specific diagnoses such as RHD are not available at
GSH. We obtained information from key clinical/hos-
pital informants and ward operational managers through
unstructured interviews and review of staff weekly duty
timesheets. Eight non-participatory observations were
conducted to understand patient management and staff
time allocation and to identify and examine costs
involved.
Total annual salary grades were obtained from the
most recent GSH financial records and divided to the
number of productive minutes. The RHD specific
personnel costs were calculated depending on the aver-
age amount of time each staff member spent on patients
which were established by non-participatory observa-
tions. The limitation of this strategy is that responses
could not be authenticated through time-motion studies;
hence it might over- or underestimate the share of time
spent on providing RHD related care.
Data analysis
Study data were entered into Microsoft Excel 2016 for
quality evaluation. This Excel costing tool is provided as
a supplementary appendix file. STATA 14 was used for
the analysis of REMEDY data (utilisation and patient
demographic characteristics) (Statacorp, 2015).
Total cost was calculated by adding the ingredients
and step-down cost estimates, while the total cost per
admission was estimated by multiplying the average cost
per inpatient day by the average length of stay. The an-
nual cost of care per-patient at each of the four clinical
units was also calculated as the product of the unit cost
(per encounter) times the annual utilisation rate. The
overall annual cost of care per patient was calculated as
the sum of annual costs at each of the four clinical units.
Where the hospital provided Outpatient Clinic care for
668 patients (with a total of 7423 visits), Medical and
ICU care for 309 patients (with 1227 hospitalisation
days), Catheterisation Laboratory cares for 301 patients
(with 1426 Cath lab admissions), and Surgical Theatre
for 56 patients (with 294 procedures). For comparison,
the total cost of providing RHD care at GSH in 2017
was extracted from the spreadsheets as the aggregate
costs at each of the four clinical units (i.e. the costs re-
quired to deliver care for all individuals with RHD, in-
cluding but not limited to the 100 REMEDY
participants).
In order to assess the impact that changes in as-
sumptions or parameters would have on final cost es-
timates; one-way deterministic sensitivity analyses
were performed. The following cost model inputs
were varied: (a) discount rate of 0, 5 and 10% on cap-
ital costs [19]; and (b) utilisation rates of the four
clinical units were varied from base values to lower
and upper 95% confidence interval estimates (per the
REMEDY database) to examine their effect on average
annual per-patient costs [17, 19].
Summary of cost categorisation
Costs were categorised as recurrent and capital (fixed).
Variable costs were also expressed as recurrent costs.
Fixed costs comprised costs of buildings, equipment and
furniture, while recurrent costs were personnel salaries,
materials and consumables, overheads (i.e. electricity,
water, telephone, sewage, laundry, security), laboratory
tests, blood transfusions and medications.
Results
Baseline characteristics of the study sample
The demographical characteristics of the REMEDY study
participants are provided in Table 1. The majority of the
participants were female (67%), with the current age of
participants ranging 24–81 years. Participants were pre-
dominately from low-income backgrounds, and most
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were unemployed. Forty-eight percent had valve surgery
at some point in their lifetime, ranging between 1980
and 2016.
The REMEDY database provided the number of visits
and admissions for the 100 patients that attended car-
diac care at GSH. Utilisation data were collected over
two consecutive years to capture longer-term rates in
clinically stable patients who only attend outpatient
clinics (i.e., less frequently); these parameters are pro-
vided in Table 2.
The unit cost of RHD services by clinical unit
Summaries of average annual per-patient costs for the
four different clinical units (outpatient, cardiac ICU and
ward, cardiac catheterisation laboratory, and surgical
theatre) are provided in Table 3, Table 4, Table 5 and
Table 6, respectively. On a per-unit basis, the cardiac
medical and ICU costs comprised a smaller proportion
of RHD costs than did the cardiac catheterisation labora-
tory and surgical theatre costs. Among cost components
estimated using the ingredients approach, medications
and staff costs were the drivers of total costs of out-
patient visits, while blood transfusions and staff costs in
inpatient medical and ICU care were the highest. Con-
sumables costs were the drivers in the cardiac catheter-
isation lab and surgical theatre.
The cost of routine medications was the major cost
driver in outpatient clinic care (74%) followed by staff
time (17% of the cost). In the catheterisation lab and
surgical theater, consumables (such as prosthetic valves
and specialized catheters) were the major drivers (51
and 44%, respectively).
In 2016 the cardiac surgery theatre at GSH performed
322 valve replacements, 56 of which were RHD-related.
The most common valve replacement types were aortic
(46%), mitral (41%), and mixed aortic and mitral (13%).
Aggregate cost of RHD care
As seen in Table 7, RHD care cost GSH an estimated
US$ 2 million in 2017. The average cost per patient-
year, based on utilisation data from the REMEDY study,
was an estimated US$ 3900 with (65%) of the total cost
being driven by surgical theatre cost. In GSH, Forty-
eight percent of the participant sample had valve surgery
at some point in their lifetime, ranging 1980 to 2016.
Consumables related to cardiac catheterisation and heart
valve surgery were the main cost drivers. Outpatient care
cost also accounts for a quarter of the total annual RHD
care burden with medications (USD239) and personnel
time (USD55) being the highest respectively.
Sensitivity analyses
Figure 1 demonstrates the effects that varying utilisation
rates at each of the four clinical units had on overall an-
nual average per-patient costs. The costs were relatively
less sensitive to variations in the discount rate (Fig. 2).
In both sets of analyses, the influence of the parameters
was largest on surgical theatre costs, since this was the
most expensive clinical unit.
Discussion
This cost analysis sought to estimate, from the provider
perspective, the annual cost of RHD care in a tertiary
centre in the Western Cape Province of South Africa.
RHD was estimated to cost GSH about USD 1.9 million
in the year 2017. These costs represent 11.2% of the total
budget for GSH in the year 2017. Triangulating these es-
timates with data from the REMEDY registry, RHD was
estimated to cost USD 3900 per patient per year in total,
with most of the total cost being driven by surgical the-
atre and cardiac catheterisation laboratory costs. Previ-
ous studies indicated that the per-patient cost of RHD
care in the United States of America in 2002 was ap-
proximately USD 6000 [20], while the per-patient cost in
China in 2012 was approximately USD 4700 [21]. A
study from Havana, Cuba also indicated that the cost of
severe RHD care in the 1990s was approximately USD
6300 [22], while a hospital-based study from Pakistan’s
largest tertiary care hospitals found that the average cost
of care per patient was USD 1179 [23]. The cost per-
patient in South Africa for merely inpatient care in 2010
was USD 2900 [24]. These costs are much higher than
Table 2 Average annual utilisation rates for RHD care at four clinical units at GSH
Clinical unit Outpatient
clinic




Per-patient utilisation rate per year (95% confidence
interval)




Table 1 Demographical characteristics of patients (n = 100) with
RHD whose medical records were used for this study
Characteristic Estimate
Mean age 48 years
Female sex 67%
Employment history Employed 17%
Self-employed 1%
Unemployed 83%
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the annual cost of the facility-level care delivery of HIV/
AIDS, drug sensitive tuberculosis, and hypertension,
which have been estimated at around USD 660 (in 2016)
[25], USD 250 (in 2015) [26], and USD 260 (in 2016)
[27] per year, respectively. Not only has managing RHD
cost more on a per-patient basis than all three of these
conditions combined, but it has also been more
neglected in national health policy discussions [28].
To the best of our knowledge, there have been no
previous costing studies on RHD in Africa and, only
one prior costing study in a low- and middle-income
country setting. A study in Brazil looking at RHD,
quantified per-patient direct costs of RHD and
rheumatic fever from the provider perspective using
the ingredients approach [29]. Even after adjusting to
a common currency and year, the cost estimates in
this study are higher than in the Brazilian study,
probably due to advances in care (i.e. new technolo-
gies) and to the fact that health sector prices tend to
rise faster than inflation. In addition, the present
study took a more detailed look at surgical care, the
most expensive aspect of RHD care.
Table 3 Outpatient total and unit costs
Cost component Annual total cost to GSH in 2017 (US$) Unit cost per encounter in 2017 (US$)
Costs obtained through step-down approach
Personnel $ 170,000 $ 55
Overheads $ 20,000 $ 5.4
Maintenance $ 2300 $ 1.7
Consumables $ 8000 $ 2.3
Building $ 25,000 $ 6.6
Equipment & furniture $ 11,000 $ 2.9
Step-down sub-total $ 240,000 $ 76
Costs obtained through ingredients approach
Medications $ 160,000 $ 240
Laboratory tests $ 23,700 $ 35
Ingredients sub-total $ 170,000 $ 250
Total cost
Sum of sub-totals $ 410,000 $ 320
Note: totals may differ slightly from individual rows due to rounding
Table 4 Cost of cardiac medical and intensive care unit care
Cost component Annual total cost to GSH in 2017 (US$) Unit cost per encounter in 2017 (US$)
Costs obtained through step-down approach
Personnel $ 93,000 $ 50
Overheads $ 31,300 $ 17
Maintenance $ 3700 $ 2.0
Consumables $ 23,400 $ 13
Building $ 36,000 $ 20
Equipment & furniture $ 3000 $ 7.2
Step-down sub-total $ 190,000 $ 110
Costs obtained through ingredients approach
Medications $ 9700 $ 32
Blood transfusions $ 14,000 $ 45
Laboratory tests $ 26,000 $ 80
Ingredients sub-total $ 49,000 $ 160
Total cost
Sum of sub-totals $ 240,000 $ 270
Note: totals may differ slightly from individual rows due to rounding
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This study assessed the cost of RHD to the public sec-
tor. It did not include ambulatory costs or admission
costs from the private sector. It also did not look at pa-
tient costs, including so-called “direct non-medical
costs” such as transport and food, which – from a soci-
etal perspective – are a significant share of healthcare
costs in South Africa [19]. However, the direct medical
costs were still substantial, and from a societal perspec-
tive, the cost of surgical care from the provider perspec-
tive is probably the most significant single driver of
costs.
It should be noted that, amongst the “direct” costs es-
timated using the ingredients approach, the main cost
contributors to outpatient RHD care were monthly
medications followed by personnel cost, while the cost
of laboratory tests, personnel and blood transfusions
were major drivers for inpatient medical and ICU ward
costs. These findings are similar to a study from
Australia in which two-thirds of the cost of ICU care in
tertiary hospitals was related to personnel [30]. Further
studies predicted that consumables expenditure (in gen-
eral) is likely to increase in the future in light of new in-
novations and therapies [31]. Along these lines, the
cardiac catheterisation lab and surgical theatre consum-
ables were found to be major drivers of cost in this
study. One implication of this study is that research on
developing cheaper, locally made prosthetic valves and
catheters should be supported, and measures should be
Table 5 Cost of catheterisation laboratory care
Cost component Annual total cost to GSH in 2017 (US$) Unit cost per encounter in 2017 (US$)
Costs obtained through step-down approach
Personnel $ 91,000 $ 290
Maintenance $ 3100 $ 10
Consumables $ 310,000 $ 970
Building $ 30,000 $ 100
Equipment & furniture $ 22,000 $ 430
Step-down sub-total $ 450,300 $ 1800
Costs obtained through ingredients approach
Medications $ 39,000 $ 130
Ingredients sub-total $ 40,000 $ 130
Total cost
Sum of sub-totals $ 490,000 $ 1900
Note: totals may differ slightly from individual rows due to rounding
Table 6 Cost of cardiac surgical theatre care
Cost component Annual total cost to GSH in 2017 (US$) Unit cost per encounter in 2017 (US$)
Costs obtained through step-down approach
Personnel $ 210,000 $ 2300
Maintenance $ 4600 $ 50
Consumables: general $ 62,000 $ 680
Consumables: perfusion $ 250,000 $ 2800
Consumables: anaesthesia $ 19,000 $ 200
Consumables: prosthetic valves $ 91,000 $ 1000
Building $ 46,000 $ 500
Equipment & furniture $ 79,000 $ 3100
Step-down sub-total $ 750,100 $ 11,000
Costs obtained through ingredients approach
Medications $ 45,000 $ 800
Ingredients sub-total $ 45,000 $ 800
Total cost
Sum of sub-totals $ 800,000 $ 12,000
Note: totals may differ slightly from individual rows due to rounding
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taken to support the production and export of such
products to other African countries [32].
This study can also be viewed as an analysis of the
economic consequences of inadequate prevention of
rheumatic fever and RHD. RHD can be entirely pre-
vented by addressing bacterial sore throat in children
using primary health centre-based approaches. When
this prevention window is missed, rheumatic fever de-
velops and can lead to heart valve damage, which can re-
quire one or more surgeries over the lifetime of affected
individuals. Several programmes in Latin America and
the Caribbean demonstrated that healthcare costs from
RHD declined by more than 90% when comprehensive
prevention efforts were undertaken [23]. However,
barriers such as poor access to primary care, shortage of
skilled staff and poor public awareness about diagnosis
and treatment of sore throats hindered wide adoption of
primary prevention of the disease. The present study
provides crucial evidence for the Western Cape Depart-
ment of Health, and the National Department of Health
to scale up RHD prevention efforts in South Africa.
Our study had a number of important limitations.
Firstly, it was a hospital-based cost analysis, with the
usual limitations of such a study design. One hundred
patient records were reviewed; however, some details
were missing, while those with severe disease were often
presented with little detail. Nevertheless, considerable ef-
fort was taken to produce accurate and relevant
Table 7 Summary costs: Aggregate costs to GSH in 2017 and estimated annual costs per-patient
Clinical unit Aggregate cost to GSH in
2017 (US$)




% share of per-patient
annual cost
Outpatient clinic $ 400,000 21% $ 930 25%
Cardiac medical intensive care
unit and ward
$ 240,000 13% $ 82 2.1%
Cardiac catheterisation lab $ 490,000 26% $ 360 9.4%
Surgical theatre $ 800,000 41% $ 2500 65%
Total $ 1,900,000 $ 3900
Note: percentages and sums may differ from totals due to rounding
Fig. 1 Effect of variation in utilisation rates on annual per-patient cost of RHD care
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estimates. Secondly, medication records did not disag-
gregate drugs related to RHD from drugs with other in-
dications, potentially leading to over-estimates of RHD-
specific medication costs. Thirdly, out of the 100-
participant sample, only 88 individuals were consistently
engaged in RHD care in GSH. This finding raises the
question of whether they were receiving care elsewhere.
As noted previously, for practical reasons, we were un-
able to gather pharmacy dispensing or emergency de-
partment costs. In total, these factors might lead to an
under-estimate of per-patient costs and GSH costs. Fi-
nally, the step-down approach is not ideal for estimating
some costs such as diagnostics (echocardiography, etc.)
and pharmacy costs, better data would allow for more
precise estimates of these costs using an ingredients ap-
proach. Notably, the cost of pharmacy services is likely
to be higher at GSH than at health facilities in the com-
munity where most individuals with RHD receive the
majority of their monthly prescriptions. Overall, our esti-
mates of average annual per-patient care costs are prob-
ably higher compared to what they would have been if
referring hospitals and clinics had been sampled.
Conclusion
In summary, we found that RHD results in considerable
costs to tertiary facilities in South Africa, a middle-
income country with a high burden of disease and rela-
tively adequate access to advanced cardiovascular care.
Per-patient costs are much higher than other essential
health conditions such as HIV/AIDS, tuberculosis, and
hypertension. The high cost of treating RHD under-
scores the urgency of scaling up rheumatic fever preven-
tion efforts in order to eliminate new cases of RHD
eventually. Our study can serve as an input to future
economic evaluations focused on RHD programmes and
interventions in South Africa. We developed a costing
framework and data collection tool (presented in Add-
itional file 2: Appendix 2) that can be expanded to other
aspects of RHD prevention and care as well as replicated
in other African settings. The systematic and widespread
collection of data on the cost of RHD will be a crucial
component of raising awareness on the importance of
the condition in Africa and of making a case for invest-
ing in RHD prevention.
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